BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

611 related articles for article (PubMed ID: 22456196)

  • 1. RhoA as a mediator of clinically relevant androgen action in prostate cancer cells.
    Schmidt LJ; Duncan K; Yadav N; Regan KM; Verone AR; Lohse CM; Pop EA; Attwood K; Wilding G; Mohler JL; Sebo TJ; Tindall DJ; Heemers HV
    Mol Endocrinol; 2012 May; 26(5):716-35. PubMed ID: 22456196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a RhoA- and SRF-dependent mechanism of androgen action that is associated with prostate cancer progression.
    Heemers HV
    Curr Drug Targets; 2013 Apr; 14(4):481-9. PubMed ID: 23469924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TACC2 is an androgen-responsive cell cycle regulator promoting androgen-mediated and castration-resistant growth of prostate cancer.
    Takayama K; Horie-Inoue K; Suzuki T; Urano T; Ikeda K; Fujimura T; Takahashi S; Homma Y; Ouchi Y; Inoue S
    Mol Endocrinol; 2012 May; 26(5):748-61. PubMed ID: 22456197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein Kinase N1 control of androgen-responsive serum response factor action provides rationale for novel prostate cancer treatment strategy.
    Venkadakrishnan VB; DePriest AD; Kumari S; Senapati D; Ben-Salem S; Su Y; Mudduluru G; Hu Q; Cortes E; Pop E; Mohler JL; Azabdaftari G; Attwood K; Shah RB; Jamieson C; Dehm SM; Magi-Galluzzi C; Klein E; Sharifi N; Liu S; Heemers HV
    Oncogene; 2019 Jun; 38(23):4496-4511. PubMed ID: 30742064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: evidence for a role for serum response factor in prostate cancer.
    Heemers HV; Regan KM; Dehm SM; Tindall DJ
    Cancer Res; 2007 Nov; 67(21):10592-9. PubMed ID: 17975004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The SRF target gene Fhl2 antagonizes RhoA/MAL-dependent activation of SRF.
    Philippar U; Schratt G; Dieterich C; Müller JM; Galgóczy P; Engel FB; Keating MT; Gertler F; Schüle R; Vingron M; Nordheim A
    Mol Cell; 2004 Dec; 16(6):867-80. PubMed ID: 15610731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Rho/MRTF/SRF inhibitors block matrix-stiffness and TGF-β-induced fibrogenesis in human colonic myofibroblasts.
    Johnson LA; Rodansky ES; Haak AJ; Larsen SD; Neubig RR; Higgins PD
    Inflamm Bowel Dis; 2014 Jan; 20(1):154-65. PubMed ID: 24280883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The RhoA/Rho kinase pathway regulates nuclear localization of serum response factor.
    Liu HW; Halayko AJ; Fernandes DJ; Harmon GS; McCauley JA; Kocieniewski P; McConville J; Fu Y; Forsythe SM; Kogut P; Bellam S; Dowell M; Churchill J; Lesso H; Kassiri K; Mitchell RW; Hershenson MB; Camoretti-Mercado B; Solway J
    Am J Respir Cell Mol Biol; 2003 Jul; 29(1):39-47. PubMed ID: 12600823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nuclear translocation of the SRF co-activator MAL in cortical neurons: role of RhoA signalling.
    Tabuchi A; Estevez M; Henderson JA; Marx R; Shiota J; Nakano H; Baraban JM
    J Neurochem; 2005 Jul; 94(1):169-80. PubMed ID: 15953360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rho/ROCK/actin signaling regulates membrane androgen receptor induced apoptosis in prostate cancer cells.
    Papadopoulou N; Charalampopoulos I; Alevizopoulos K; Gravanis A; Stournaras C
    Exp Cell Res; 2008 Oct; 314(17):3162-74. PubMed ID: 18694745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen-responsive serum response factor target genes regulate prostate cancer cell migration.
    Verone AR; Duncan K; Godoy A; Yadav N; Bakin A; Koochekpour S; Jin JP; Heemers HV
    Carcinogenesis; 2013 Aug; 34(8):1737-46. PubMed ID: 23576568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
    Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
    Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen action in the prostate gland.
    Yadav N; Heemers HV
    Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer.
    McGrath MJ; Binge LC; Sriratana A; Wang H; Robinson PA; Pook D; Fedele CG; Brown S; Dyson JM; Cottle DL; Cowling BS; Niranjan B; Risbridger GP; Mitchell CA
    Cancer Res; 2013 Aug; 73(16):5066-79. PubMed ID: 23801747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inactivation of androgen-induced regulator ARD1 inhibits androgen receptor acetylation and prostate tumorigenesis.
    Wang Z; Wang Z; Guo J; Li Y; Bavarva JH; Qian C; Brahimi-Horn MC; Tan D; Liu W
    Proc Natl Acad Sci U S A; 2012 Feb; 109(8):3053-8. PubMed ID: 22315407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Megakaryoblastic leukemia 1, a potent transcriptional coactivator for serum response factor (SRF), is required for serum induction of SRF target genes.
    Cen B; Selvaraj A; Burgess RC; Hitzler JK; Ma Z; Morris SW; Prywes R
    Mol Cell Biol; 2003 Sep; 23(18):6597-608. PubMed ID: 12944485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PAGE4 positivity is associated with attenuated AR signaling and predicts patient survival in hormone-naive prostate cancer.
    Sampson N; Ruiz C; Zenzmaier C; Bubendorf L; Berger P
    Am J Pathol; 2012 Oct; 181(4):1443-54. PubMed ID: 22885105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence.
    Kahl P; Gullotti L; Heukamp LC; Wolf S; Friedrichs N; Vorreuther R; Solleder G; Bastian PJ; Ellinger J; Metzger E; Schüle R; Buettner R
    Cancer Res; 2006 Dec; 66(23):11341-7. PubMed ID: 17145880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased PrLZ-mediated androgen receptor transactivation promotes prostate cancer growth at castration-resistant stage.
    Li L; Xie H; Liang L; Gao Y; Zhang D; Fang L; Lee SO; Luo J; Chen X; Wang X; Chang LS; Yeh S; Wang Y; He D; Chang C
    Carcinogenesis; 2013 Feb; 34(2):257-67. PubMed ID: 23104178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells.
    Yang M; Wang J; Wang L; Shen C; Su B; Qi M; Hu J; Gao W; Tan W; Han B
    Prostate; 2015 Sep; 75(13):1363-75. PubMed ID: 26015225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.